liposome based vaccine (Xeme Biopharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameliposome based vaccine (Xeme Biopharma)
Drug Alias NameMLCV liposome vaccine (Xeme)multilamellar coalescence vesicle vaccine (Xeme)
ClassificationBiologics > Antigen > Tumor antigenVaccines > Application > Therapeutic vaccine
Mechanisms of ActionInterleukin-2 receptor agonistsGranulocyte-macrophage colony-stimulating factor receptor stimulants
TargetsGranulocyte-macrophage colony-stimulating factor receptorInterleukin-2 receptor
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesXeme Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXeme Biopharma Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A